%0 Journal Article
%A Apostolova, Petya
%A Kreutmair, Stefanie
%A Toffalori, Cristina
%A Punta, Marco
%A Unger, Susanne
%A Burk, Ann-Cathrin
%A Wehr, Claudia
%A Maas-Bauer, Kristina
%A Melchinger, Wolfgang
%A Haring, Eileen
%A Hoefflin, Rouven
%A Shoumariyeh, Khalid
%A Hupfer, Valerie
%A Lauer, Eliza Maria
%A Duquesne, Sandra
%A Lowinus, Theresa
%A Gonzalo Núñez, Nicolás
%A Alberti, Chiara
%A da Costa Pereira, Sara
%A Merten, Carla Helena
%A Power, Laura
%A Weiss, Matthias
%A Böke, Caroline
%A Pfeifer, Dietmar
%A Marks, Reinhard
%A Bertz, Hartmut
%A Wäsch, Ralph
%A Ihorst, Gabriele
%A Gentner, Bernhard
%A Duyster, Justus
%A Börries, Melanie
%A Andrieux, Geoffroy
%A Finke, Juergen
%A Becher, Burkhard
%A Vago, Luca
%A Zeiser, Robert
%T Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response.
%J British journal of haematology
%V 203
%N 2
%@ 0007-1048
%C Oxford [u.a.]
%I Wiley-Blackwell
%M DKFZ-2023-01580
%P 264-281
%D 2023
%Z 2023 Oct;203(2):264-281
%X Acute myeloid leukaemia (AML) relapse after allogeneic haematopoietic cell transplantation (allo-HCT) is often driven by immune-related mechanisms and associated with poor prognosis. Immune checkpoint inhibitors combined with hypomethylating agents (HMA) may restore or enhance the graft-versus-leukaemia effect. Still, data about using this combination regimen after allo-HCT are limited. We conducted a prospective, phase II, open-label, single-arm study in which we treated patients with haematological AML relapse after allo-HCT with HMA plus the anti-PD-1 antibody nivolumab. The response was correlated with DNA-, RNA- and protein-based single-cell technology assessments to identify biomarkers associated with therapeutic efficacy. Sixteen patients received a median number of 2 (range 1-7) nivolumab applications. The overall response rate (CR/PR) at day 42 was 25
%K acute myeloid leukaemia (Other)
%K allogeneic haematopoietic cell transplantation (Other)
%K hypomethylating agent (Other)
%K immune checkpoint inhibition (Other)
%K immune phenotype (Other)
%K relapse (Other)
%K single-cell RNA-sequencing (Other)
%K single-cell immunomonitoring (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37539479
%R 10.1111/bjh.19007
%U https://inrepo02.dkfz.de/record/277924